Wallis Christopher J D, Nam Robert K
Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto , Toronto, Ontario, Canada.
EJIFCC. 2015 Mar 10;26(2):79-91. eCollection 2015 Mar.
Over the past decades, research has focussed on identifying the genetic underpinnings of prostate cancer. It has been recognized that a number of forms of genetic changes coupled with epigenetic and gene expression changes can increase the prediction to develop prostate cancer. This review outlines the role of somatic copy number alterations (SCNAs), structural rearrangements, point mutations, and single nucleotide polymorphisms (SNPs) as well as miRNAs. Identifying relevant genetic changes offers the ability to develop novel biomarkers to allow early and accurate detection of prostate cancer as well as provide risk stratification of patients following their diagnosis. The concept of personalized or individualized medicine has gained significant attention. Therefore, a better understanding of the genetic and metabolic pathways underlying prostate cancer development offers the opportunity to explore new therapeutic interventions with the possibility of offering patient-specific targeted therapy.
在过去几十年里,研究一直聚焦于确定前列腺癌的遗传基础。人们已经认识到,多种形式的基因变化,再加上表观遗传和基因表达变化,会增加患前列腺癌的预测性。本综述概述了体细胞拷贝数改变(SCNAs)、结构重排、点突变、单核苷酸多态性(SNPs)以及微小RNA(miRNAs)的作用。识别相关的基因变化能够开发新的生物标志物,以便早期准确检测前列腺癌,并在患者确诊后进行风险分层。个性化或个体化医疗的概念已受到广泛关注。因此,更好地了解前列腺癌发生背后的遗传和代谢途径,为探索新的治疗干预措施提供了机会,有可能提供针对患者的靶向治疗。